[ Promentis Pharmaceuticals raises $26M in Series C ]

Promentis Pharmaceuticals has raised $26 million in Series C funding.

Founded in 2006, Promentis Pharmaceuticals is a  privately-held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders.

This financing will enable Promentis to advance its lead compound SXC-2023 through Phase 2 clinical proof of concept. SXC-2023 is a novel small molecule designed to engage System Xc-, a CNS target addressing glutamatergic dysfunction and oxidative stress, with a compelling profile across a range of pre-clinical studies.

Funding  Series C
Founded  2006
Country  USA
City  Milwaukee, Wisconsin
Founder / CEO  Klaus Veitinger
Deal Size  $26M
Investors  Golden Triangle Angel Network
 OrbiMed
 Aisling Capital
 F-Prime Capital Partners
 Black Pearl Capital Partners
Previous Investors  Golden Angels Investors
 Black Horse Investments
 National Institutes of Health

[adyen action=”checkout_button”]